Distribution of histologic subtypes and clinical characteristics in the entire cohort (N = 755)
| Clinical characteristics . | All patients (N = 755) . | ALCL, ALKpos (n = 68) . | ALCL, ALKneg (n = 115) . | ALCL, ALKu (n = 36) . | PTCL NOS (n = 256) . | AITL (n =104) . | EATL (n = 68) . | TCL U (n = 57) . | NK/T, nt (n = 33) . | SPTCL (n = 12) . | HSTCL (n = 8) . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (y), median (range) | 67 (18-96) | 41 (18-81)* | 67 (19-93) | 69 (31-89) | 69 (18-96) | 70 (33-88) | 68 (35-88) | 72 (30-94) | 62 (26-91) | 58 (20-73)† | 47 (18-72) |
| Male | 445 (59) | 37 (54) | 80 (70) | 21 (58) | 148 (58) | 59 (57) | 40 (59) | 34 (60) | 20 (61) | 6 (50) | 4 (50) |
| Female | 310 (41) | 31 (46) | 37 (30) | 14 (42) | 108 (42) | 45 (43) | 28 (41) | 25 (40) | 13 (39) | 6 (50) | 4 (50) |
| B symptoms | 444 (59) | 40 (59) | 61 (52) | 20 (57) | 155 (61) | 74 (71)‡ | 37 (54) | 31 (53) | 15 (46) | 6 (50) | 6 (75) |
| Stage III-IV | 490 (65) | 33 (49) | 68 (59) | 18 (50) | 184 (72) | 93 (89)§ | 28 (41) | 40 (70)|| | 14 (42) | 7 (58) | 7 (88) |
| BM | 154 (20) | 6 (9)¶ | 16 (13) | 6 (17) | 56 (22) | 37 (36)# | 1 (2) | 26 (44) | 1 (3) | — | 5 (63) |
| Extranodal involvement >1 | 110 (15) | 5 (7)** | 17 (15) | 4 (11) | 35 (14) | 12 (12) | 16 (24)¶ | 12 (20) | 6 (18) | 1 (8) | 3 (38) |
| WHO PS >1 | 267 (35) | 16 (24)¶ | 40 (34) | 8 (29) | 92 (36) | 35 (35) | 24 (38) | 26 (47) | 6 (18) | 4 (33) | 4 (50) |
| Bulky disease (>10 cm) | 81 (11) | 11 (16)†† | 18 (15) | 3 (8) | 27 (11) | 5 (5) | 7 (10) | 6 (10) | 1 (3) | 1 (8) | 2 (25) |
| LDH > ULN | 441 (54) | 31 (46) | 61 (52) | 19 (54) | 162 (63) | 77 (74)‡‡ | 16 (24)§§ | 39 (66)|||| | 17 (52) | 11 (92) | 8 (100) |
| IPI 0-1 | 170 (23) | 36 (53)¶¶ | 37 (32) n | 11 (31)## | 41 (16)*** | 4 (4)††† | 25 (37) | 5 (9)††† | 9 (27) | 2 (17) | — |
| IPI 2-3 | 386 (51) | 26 (38)## | 46 (40)‡‡‡ | 14 (39)§§§ | 141 (55)|||||| | 68 (65)|||||| | 26 (38) | 35 (61)|||||| | 17 (52) | 8 (67) | 6 (75) |
| IPI 4-5 | 139 (18) | 4 (6)¶¶¶ | 26 (23) p | 6 (17) | 58 (23)††† | 26 (25)### | 8 (12) | 6 (11) | 1 (3) | 2 (17) | 2 (25) |
| 5-y OS (%) | 34.1 | 79.4 | 38.4 | 27.8 | 28.1 | 31.6 | 20.4 | 24.6 | 20.5 | 58.3 | 42.9 |
| 5-y PFS (%) | 25.7 | 63.2 | 31.4 | 25.0 | 21.3 | 20.4 | 17.6 | 15.1 | 13.8 | 40.0 | 20.0 |
| Clinical characteristics . | All patients (N = 755) . | ALCL, ALKpos (n = 68) . | ALCL, ALKneg (n = 115) . | ALCL, ALKu (n = 36) . | PTCL NOS (n = 256) . | AITL (n =104) . | EATL (n = 68) . | TCL U (n = 57) . | NK/T, nt (n = 33) . | SPTCL (n = 12) . | HSTCL (n = 8) . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (y), median (range) | 67 (18-96) | 41 (18-81)* | 67 (19-93) | 69 (31-89) | 69 (18-96) | 70 (33-88) | 68 (35-88) | 72 (30-94) | 62 (26-91) | 58 (20-73)† | 47 (18-72) |
| Male | 445 (59) | 37 (54) | 80 (70) | 21 (58) | 148 (58) | 59 (57) | 40 (59) | 34 (60) | 20 (61) | 6 (50) | 4 (50) |
| Female | 310 (41) | 31 (46) | 37 (30) | 14 (42) | 108 (42) | 45 (43) | 28 (41) | 25 (40) | 13 (39) | 6 (50) | 4 (50) |
| B symptoms | 444 (59) | 40 (59) | 61 (52) | 20 (57) | 155 (61) | 74 (71)‡ | 37 (54) | 31 (53) | 15 (46) | 6 (50) | 6 (75) |
| Stage III-IV | 490 (65) | 33 (49) | 68 (59) | 18 (50) | 184 (72) | 93 (89)§ | 28 (41) | 40 (70)|| | 14 (42) | 7 (58) | 7 (88) |
| BM | 154 (20) | 6 (9)¶ | 16 (13) | 6 (17) | 56 (22) | 37 (36)# | 1 (2) | 26 (44) | 1 (3) | — | 5 (63) |
| Extranodal involvement >1 | 110 (15) | 5 (7)** | 17 (15) | 4 (11) | 35 (14) | 12 (12) | 16 (24)¶ | 12 (20) | 6 (18) | 1 (8) | 3 (38) |
| WHO PS >1 | 267 (35) | 16 (24)¶ | 40 (34) | 8 (29) | 92 (36) | 35 (35) | 24 (38) | 26 (47) | 6 (18) | 4 (33) | 4 (50) |
| Bulky disease (>10 cm) | 81 (11) | 11 (16)†† | 18 (15) | 3 (8) | 27 (11) | 5 (5) | 7 (10) | 6 (10) | 1 (3) | 1 (8) | 2 (25) |
| LDH > ULN | 441 (54) | 31 (46) | 61 (52) | 19 (54) | 162 (63) | 77 (74)‡‡ | 16 (24)§§ | 39 (66)|||| | 17 (52) | 11 (92) | 8 (100) |
| IPI 0-1 | 170 (23) | 36 (53)¶¶ | 37 (32) n | 11 (31)## | 41 (16)*** | 4 (4)††† | 25 (37) | 5 (9)††† | 9 (27) | 2 (17) | — |
| IPI 2-3 | 386 (51) | 26 (38)## | 46 (40)‡‡‡ | 14 (39)§§§ | 141 (55)|||||| | 68 (65)|||||| | 26 (38) | 35 (61)|||||| | 17 (52) | 8 (67) | 6 (75) |
| IPI 4-5 | 139 (18) | 4 (6)¶¶¶ | 26 (23) p | 6 (17) | 58 (23)††† | 26 (25)### | 8 (12) | 6 (11) | 1 (3) | 2 (17) | 2 (25) |
| 5-y OS (%) | 34.1 | 79.4 | 38.4 | 27.8 | 28.1 | 31.6 | 20.4 | 24.6 | 20.5 | 58.3 | 42.9 |
| 5-y PFS (%) | 25.7 | 63.2 | 31.4 | 25.0 | 21.3 | 20.4 | 17.6 | 15.1 | 13.8 | 40.0 | 20.0 |
Data are missing for B symptoms (n = 22), stage III-IV (n = 23), bone marrow (n = 1), extranodal involvement >1 (n = 1), bulky disease (n = 20), lactate dehydrogenase (n = 37), and IPI (n = 59). Footnotes denominate statistically significant differences between groups as indicated. For exact P values, see supplemental Table 1.
BM, bone marrow; LDH, lactate dehydrogenase; ULN, upper limit of normal.
P < .05 vs all subtypes except SPTCL.
P < .05 all subtypes except vs ALKpos ALCL and NK/T, nt.
P < .05 vs ALKneg ALCL, PTCL NOS, EATL, and NK/T, nt.
P < .05 vs all other subtypes.
P < .05 vs ALKpos ALCL and ALKu ALCL.
P < .05 vs PTCL NOS.
P < .05 vs ALKneg ALCL and PTCL NOS.
P < .05 vs EATL and TCL U.
P < .05 vs AITL.
P < .05 vs ALKpos and ALKneg ALCL, PTCL NOS, and EATL.
P < .05 vs ALKneg ALCL, ALKu ALCL, PTCL NOS, AITL, and NK/T, nt.
P < .05 vs PTCL NOS and ALKpos ALCL.
P < .05 vs all subgroups except ALKu ALCL and EATL.
P < .05 vs PTCL NOS, AITL, and TCL U.
P < .05 vs AITL and EATL.
P < .05 vs EATL and NK/T, nt.
P < .05 vs PTCL NOS and AITL.
P < .05 vs AITL and TCL U.
P < .05 vs EATL.
P < .05 vs ALKneg ALCL, PTCL NOS, AITL, and TCL U.
P < .05 vs TCL U, EATL, and NK/T, nt.